BRIDION (nda022225)- (EQ 500MG BASE/5ML (EQ 100MG BASE/ML),EQ 200MG BASE/2ML (EQ 100MG BASE/ML))

Generic Name	SUGAMMADEX SODIUM	Innovator	MSD SUB MERCK
Dosage	EQ 500MG BASE/5ML (EQ 100MG BASE/ML),EQ 200MG BASE/2ML (EQ 100MG BASE/ML)
ParaIV Filing	Yes	505(b)2 Filing	No
Last Patent Expiry	2026-Jul-27	NCE Excl Expiry	2020-Dec-15
ODE Expiry	None	NP Expiry	None
GAIN Expiry	None	Drug Complexity	No
Indication	BRIDION is indicated for the reversal of neuromuscular blockade induced by rocuronium bromide and vecuronium bromide in adults and pediatric patients aged 2 years and older undergoing surgery.

Approvals and Launches

Final Approvals	Tentative Approvals	Generic Launches
4	9	1

Other Developers

Total Other Developers	32

Drugs with Suitability

Drugs with Suitability	No

Drug Pricing

	NDA			ANDA
Dosage	Weekly	Monthly	Yearly	Yearly Up	Yearly Down
EQ 500MG BASE/5ML (EQ 100MG BASE/ML)	**	**	-	-	-
EQ 200MG BASE/2ML (EQ 100MG BASE/ML)	**	**	-	-	-

Drug Sales

NDA Sales Available	Total Generic Sales Available
Yes	0

Manufacturing Details of BRIDION